Primary source: About the Federal Register
A public meeting regarding the reauthorization of PDUFA will take place on September 16, 2026, alongside a request for public comments that must be submitted by October 16, 2026.
The reauthorization of PDUFA will shape the regulatory framework and funding for drug review and safety oversight, impacting the speed and scale of safety signal detection and the FDA's capacity for post-approval safety monitoring.
Stakeholders must prepare to submit comments regarding the proposed recommendations for PDUFA reauthorization by the deadline of October 16, 2026.
Regulatory Intelligence Lead
Review before 2026-10-16.
Proposals for PDUFA VIII funding levels and performance goals; recommendations for enhancing safety reporting infrastructure, the Sentinel System, and the review of postmarketing safety data; opportunities for stakeholder input on pharmacovigilance resource allocation.
PDUFA reauthorization is the primary legislative mechanism for setting pharmacovigilance policy and funding in the US. The proposed initiatives directly impact the scale and speed of safety signal detection, the modernization of adverse event reporting systems, and the overall capacity of the FDA to conduct post-approval safety monitoring.
Stakeholders must prepare to submit comments regarding the proposed recommendations for PDUFA reauthorization by the deadline of October 16, 2026.
The FDA is announcing a hybrid public meeting on September 16, 2026, requesting public comments by October 16, 2026, on the recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA VIII) for fiscal years 2028 through 2032.
What changed: A public meeting regarding the reauthorization of PDUFA will take place on September 16, 2026, alongside a request for public comments that must be submitted by October 16, 2026.
Why it matters: The reauthorization of PDUFA will shape the regulatory framework and funding for drug review and safety oversight, impacting the speed and scale of safety signal detection and the FDA's capacity for post-approval safety monitoring.
Practical implication: Stakeholders must prepare to submit comments regarding the proposed recommendations for PDUFA reauthorization by the deadline of October 16, 2026.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
